Stock Insider Trading (from SEC Form 4)

SYK / Stryker Corp. insiders include STRYKER RONDA E (), Benscoter Steven P (VP, Human Resources), Sagar Bijoy (VP, Chief Information Officer), Subrahmanian Ramesh (Group President), Golston Allan C., Berry William E Jr (VP, Corporate Controller), Silvernail Andrew K (), McLean Graham A (President, Asia-Pacific), Becker Yin C (VP, Comm & Public Affairs), Scannell Timothy J (Group President), Hutchinson Michael David (General Counsel), Boehnlein Glenn S (VP, Chief Financial Officer), Floyd David (Group President, Orthopaedics) COX HOWARD E JR (), Carpenter Lonny J (Group President), Lobo Kevin (Chairman and CEO), Datar Srikant, PARFET WILLIAM U (), and Doliveux Roch (), Owen Katherine Ann (V.P., Strategy & Investor Rel.), Fink M Kathryn (VP, Global Human Resources), FRANCESCONI LOUISE (), .

Stryker Corp. insider trades are found here. Insiders are officers, directors, or significant investors in a company. In general, it is generally illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.

Job titles are listed as of the filing and may not be current. Click the link icon to see the full transaction history.

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.
File Date
Tran Date
Insider Code Shares Post Shares Percent
Tran Value Post Value Percent
2018-02-06 2018-02-05 McLean Graham A President, Asia-Pacific
S -1,738 4,440 -28.13 160.66 -279,227 713,330 -39.14
2018-02-05 2018-02-02 Carpenter Lonny J Group President
S -5,000 96,965 -4.90 163.7584 -818,792 15,878,833 -5.16
2018-02-05 2017-01-31 Doliveux Roch Director
P 43 18,797 0.23 164.9424 7,093 3,100,422 0.23
2018-02-05 2018-02-02 COX HOWARD E JR Director
S -7,400 524,732 -1.39 164.0893 -1,214,261 86,102,907 -1.41
2018-02-05 2018-02-01 Berry William E Jr VP, Corporate Controller
S -1,306 346 -79.06 164.418 -214,730 56,889 -377.46
2018-02-05 2018-02-01 FRANCESCONI LOUISE Director
S -4,347 17,557 -19.85 164.1718 -713,655 2,882,364 -24.76
2018-01-24 2018-01-23 STRYKER RONDA E Director
M 7,400 23,767,043 0.03 67.80 501,720
2017-12-04 2017-11-30 Fink M Kathryn VP, Global Human Resources
S -150 6,125 -2.39 154.46 -23,169 946,068 -2.45
2017-11-02 2017-11-01 Silvernail Andrew K Director
G -1,300 1,652 -44.04
2017-07-25 2017-07-21 Sagar Bijoy VP, Chief Information Officer
F -907 1,611 -36.02 147.40 -133,692
2017-07-15 2017-07-12 Floyd David Group President, Orthopaedics
S -19,305 21,861 -46.90 144.56 -2,790,731 3,160,226 -88.31
2017-05-03 2017-05-02 Scannell Timothy J Group President
S -13,322 119,681 -10.02 135.8941 -1,810,381 16,263,942 -11.13
2017-05-03 2017-05-01 Lobo Kevin Chairman and CEO, Director
S -9,539 48,500 -16.44 135.8169 -1,295,557 6,587,120 -19.67
2017-03-23 2017-03-21 Datar Srikant Director
M 915 8,557 11.97
2017-03-23 2017-03-21 Golston Allan C. Director
M 915 8,307 12.38
2017-03-23 2017-03-21 Becker Yin C VP, Comm & Public Affairs
F -1,617 16,285 -9.03 132.59 -214,398
2017-03-23 2017-03-21 Boehnlein Glenn S VP, Chief Financial Officer
F -340 4,877 -6.52 132.59 -45,081
2017-03-23 2017-03-21 Hutchinson Michael David General Counsel
F -382 8,390 -4.35 132.59 -50,649
2017-03-23 2017-03-21 Owen Katherine Ann V.P., Strategy & Investor Rel.
F -2,377 12,076 -16.45 132.59 -315,166
2016-05-26 2016-04-25 PARFET WILLIAM U Director
G -1,165 317,520 -0.37
2015-03-25 2015-03-24 Benscoter Steven P VP, Human Resources
S -1,162 6,457 -15.25 93.9817 -109,207 606,840 -18.00
2015-03-24 2015-03-21 Subrahmanian Ramesh Group President
F -1,794 20,619 -8.00 93.65 -168,008
Open market or private purchase of non-derivative or derivative security
Open market or private sale of non-derivative or derivative security
Grant, award, or other acquisition of securities from the company (such as an option)
Conversion of derivative
Sale or transfer of securities back to the company
Payment of exercise price or tax liability using portion of securities received from the company
Gift of securities by or to the insider
Equity swaps and similar hedging transactions
Exercise or conversion of derivative security received from the company (such as an option)
A transaction voluntarily reported on Form 4
Other (accompanied by a footnote describing the transaction)

Related News Stories

Why Stryker Will Likely Continue Delivering Strong Growth

13h seekingalpha
The company's stock price has faltered some recently, but is still up significantly over the past 12 months. (12-0)

Precision Therapeutics: An Unloved Medical Device Company With Significant Upside Potential

2018-02-05 seekingalpha
Recently announced projected sales of patented Streamway Machines for 2018 that amount to a 900% increase over 2017. (13-0)

Tracking Yacktman Asset Management Portfolio - Q4 2017 Update

2018-02-04 seekingalpha
This article is part of a series that provides an ongoing analysis of the changes made to Yacktman’s US stock portfolio on a quarterly basis. It is based on Yacktman Asset Management’s regulatory 13F Form filed on 02/02/2018. Please visit our Tracking Yacktman Asset Management series to get an idea of his investment philosophy and our previous update for the fund’s moves during Q3 2017. (545-3)

Stryker Producing Excellent Results, But Expectations Are High

2018-01-31 seekingalpha
Stryker delivered another great quarter of revenue growth, with strong results in Ortho, MedSurg, and Neuro. (17-0)

Stryker (SYK) Beats Earnings and Revenue Estimates in Q4

2018-01-31 zacks
Maintaining the streak of positive earnings surprises, Stryker Corporation (SYK - Free Report) reported fourth-quarter 2017 adjusted earnings per share of $1.96, beating the Zacks Consensus Estimate by a penny. Revenues of $3.47 billion outpaced the Zacks Consensus Estimate of $3.44 billion. Notably, revenues improved 9.9% year over year. Adjusted earnings per share increased 10.1% from the year-ago quarter. (15-0)

3 Stocks to Watch on Wednesday: Illumina, Inc. (ILMN), Juniper Networks, Inc. (JNPR) and Stryker Corporation (SYK) | InvestorPlace

2018-01-31 investorplace
U.S. equities suffer their worst loss since Aug. 17, 2017 due to bond market weakness, a dip in the U.S. dollar and concern over upcoming tech stocks’ earnings reports. The S&P 500 Index and Dow Jones Industrial Average fell 1.4% apiece, while the Nasdaq Composite lost 0.9%. (10-0)

Stryker's (SYK) CEO Kevin Lobo on Q4 2017 Results - Earnings Call Transcript

2018-01-31 seekingalpha
Welcome to the Fourth Quarter 2017 Stryker Earnings Call. My name is Sandra and I will be your operator for today's call. At this time, all participants are in a listen-only mode. Following the conference, we will conduct a question-and-answer session. During that time, participants will have the opportunity to ask one question and one follow-up question. [Operator Instructions] This conference call is being recorded for replay purposes. (50-0)

MedTech Stock Q4 Earnings Slated for Jan 30: SYK, ZBH, ALGN

2018-01-29 zacks
The fourth-quarter earnings season has commenced on a positive note for most sectors, with a decent picture from the 133 S&P 500 participants that have reported till Jan 26. Total earnings for these companies are up 12.3% year over year on 8.8% higher revenues, with 81.2% beating earnings estimates and 78.9% surpassing top-line expectations. (69-0)

Top Research Reports for Microsoft, Philip Morris and 3M

2018-01-23 zacks
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Microsoft (MSFT), Philip Morris (PM) and 3M (MMM). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today. (89-0)

Will Core Segmental Growth Aid Stryker (SYK) in Q4 Earnings?

2018-01-23 zacks
Stryker Corporation’s (SYK - Free Report) fourth-quarter 2017 results are scheduled for release on Jan 30, 2018, after the market closes. In the said quarter, the company is expected to witness year-over-year revenue growth in all other business segments apart from Orthopedics, Medsurg and Neurotechnology and Spine. (85-0)